Sugi Predict

Sugi Predict / Compounds / SCHEMBL7921977

SCHEMBL7921977

SCHEMBL7921977

COC(=O)[C@@H]1C[C@H](OC)CN1C(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ UCHL1 P09936 1/20 0.46
▸ MMP2 P08253 2/20 0.42
▸ ANPEP P15144 2/20 0.42
▸ P2RX3 P56373 1/20 0.41
▸ NR1H2 P55055 2/20 0.41
▸ NR1H3 Q13133 1/20 0.41
▸ PTPN1 P18031 1/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ PDE4B Q07343 1/20 0.35
▸ HTRA1 Q92743 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MCL1 Q07820 1/20 0.34
▸ CCR2 P41597 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8269126 1.00 UCHL1 (0.46) UCHL1MMP2ANPEPP2RX3NR1H2
SCHEMBL3833792 1.00 UCHL1 (0.46) UCHL1MMP2ANPEPP2RX3NR1H2
SCHEMBL92870 1.00 UCHL1 (0.46) UCHL1MMP2ANPEPP2RX3NR1H2
SCHEMBL6857673 1.00 UCHL1 (0.46) UCHL1MMP2ANPEPP2RX3NR1H2
SCHEMBL10215471 1.00 UCHL1 (0.46) UCHL1MMP2ANPEPP2RX3NR1H2
SCHEMBL19388625 1.00 UCHL1 (0.46) UCHL1MMP2ANPEPP2RX3NR1H2
SCHEMBL13163958 1.00 UCHL1 (0.46) UCHL1MMP2ANPEPP2RX3NR1H2
SCHEMBL31107813 0.92 UCHL1 (0.47) UCHL1MMP2ANPEPP2RX3NR1H2
SCHEMBL24739170 0.90 MMP2 (0.41) UCHL1MMP2ANPEPP2RX3NR1H2
SCHEMBL18586768 0.90 MMP2 (0.41) UCHL1MMP2ANPEPP2RX3NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4606377-A2 NOVEL AMINO PYRIMIDINE DERIVATIVES Novartis AG (CH) 2025-08-27 — — EP disclosed
EP-4219478-B1 METHOD OF PREPARING AMINO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2025-06-11 — — EP disclosed
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 — — US disclosed
US-20230312483-A1 Amino Pyrimidine Derivatives NOVARTIS AG (CH) 2023-10-05 — — US disclosed
US-20230312483-A1 Amino Pyrimidine Derivatives NOVARTIS AG (CH) 2023-10-05 — — US disclosed
US-20230312483-A1 Amino Pyrimidine Derivatives NOVARTIS AG (CH) 2023-10-05 — — US disclosed
WO-2023180189-A1 MPRO TARGETING ANTIVIRAL COMPOUNDS EXSCIENTIA AI LIMITED (GB) 2023-09-28 — — WO disclosed
EP-4234551-A2 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2023-08-30 — — EP disclosed
EP-4219478-A1 METHOD OF PREPARING AMINO PYRIMIDINE DERIVATIVES Novartis AG (CH) 2023-08-02 — — EP disclosed
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2023-06-22 — — US disclosed
US-20150023913-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2015-01-22 — — US disclosed
WO-2015005901-A1 COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-15 — — WO disclosed
WO-2013106520-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2013-07-18 — — WO disclosed
US-20130183269-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-07-18 — — US disclosed
US-20130183269-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-07-18 — — US disclosed
WO-2013095275-A1 NOVEL HEPATITIS C VIRUS INHIBITORS MEDIVIR AB (SE) 2013-06-27 — — WO disclosed
WO-2010036551-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-04-01 — — WO disclosed
WO-2008005565-A9 ANTIVIRAL PHOSPHINATE COMPOUNDS GILEAD SCIENCES INC (US) 2009-01-29 — — WO disclosed
US-20070232601-A1 Vla-4 Inhibitor DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-10-04 — — US disclosed
US-20070232601-A1 Vla-4 Inhibitor DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-10-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 UCHL1 4354/4885MMP2 3326/4885ANPEP 3538/4885
US-20070232601-A1 Vla-4 Inhibitor VCAM1, ITGB4, ITGA4 UCHL1 4517/4885MMP2 975/4885ANPEP 1916/4885
US-20130183269-A1 Hepatitis C Virus Inhibitors HAVCR2, MAVS, EIF2AK2 UCHL1 1667/4885MMP2 3085/4885ANPEP 369/4885
US-20230312483-A1 Amino Pyrimidine Derivatives BTK, LCK, JAK1 UCHL1 4739/4885MMP2 4879/4885ANPEP 2081/4885
US-20150023913-A1 Hepatitis C Virus Inhibitors HAVCR2, MAVS, EIF2AK2 UCHL1 1667/4885MMP2 3085/4885ANPEP 369/4885
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 UCHL1 4354/4885MMP2 3326/4885ANPEP 3538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.